IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
In light of the emerging data from the company's ongoing randomized clinical trial of aplitabart in second-line metastatic colorectal cancer, together with the significant opportunity in autoimmunity, the company has decided to reduce workforce and minimize its future spending on the research and clinical development of aplitabart and other oncology candidates.On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseases.
IGm生物科學公司（納斯達克: IGMS）週二宣佈戰略轉變和管道轉型，加快並深化其在開發針對自身免疫性疾病的t細胞結合Igm抗體方面的領導地位。
The company's lead candidates include imvotamab, which is being developed for rheumatoid arthritis, systemic lupus erythematosus, and myositis, and IGM-2644, which is expected to enter a clinical study for generalized myasthenia gravis by the end of 2024.
公司的主要候選藥品包括imvotamab，該藥正在開發用於類風溼性關節炎、系統性紅斑狼瘡和肌炎，以及IGm-2644，預計將於2024年年底進入用於全身性重症肌無力的臨床研究。
IGM to minimize future spending on aplitabart and other oncology candidates.
IGm將盡量減少未來在aplitabart和其他腫瘤候選藥品上的支出。
In light of the emerging data from the company's ongoing randomized clinical trial of aplitabart in second-line metastatic colorectal cancer, together with the significant opportunity in autoimmunity, the company has decided to reduce workforce and minimize its future spending on the research and clinical development of aplitabart and other oncology candidates.
鑑於公司正在進行的關於aplitabart在次線轉移性結直腸癌治療中的隨機臨床試驗的新數據，以及在自身免疫疾病領域的重大機遇，公司決定減少員工數量並最小化未來在aplitabart和其他腫瘤候選藥品的研究和臨床開發支出。
The company expected to release aplitabart top-line progression-free survival results from randomized colorectal cancer trial by the end of the first quarter of 2025.
公司預計將於2025年第一季度末發佈有關aplitabart在隨機結直腸癌試驗中的頂級無進展生存結果。
As a result of these actions, IGM believes it can extend its current cash runway into 2027.
由於這些舉措，igm相信可以將目前的現金儲備延長至2027年。
As part of the company's strategic pivot to autoimmunity, Fred Schwarzer, CEO, President, and Director, and Bruce Keyt, chief scientific officer, will step down from their current roles.
作爲公司戰略轉向自身免疫性的一部分，CEO、總裁和董事Fred Schwarzer以及首席科學官Bruce Keyt將從各自的現任職務中辭職。
IGM has appointed ex-Bristol Myers Squibb & Co's executive (NYSE:BMY) Mary Beth Harler as the CEO.
IGm已任命前百時美施貴寶（紐交所: BMY）執行高級副總裁Mary Beth Harler爲CEO。
Chris Takimoto, Chief Medical Officer, has also announced to step down.
首席醫療官Chris Takimoto也宣佈將辭職。
Price Action: IGMS stock is down 13.20% at $14.36 at the last check on Tuesday.
價格走勢：週二最後檢查時，IGMS股價下跌13.20%，至14.36美元。
- Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients.
- Eli Lilly計劃在非肥胖患者中爲減肥藥物進行新試驗。
譯文內容由第三人軟體翻譯。